Your right TOP LINE data is coming out in the end of 2019.Safety data was reported back in may with the new MTD.Any poster who thinks the data coming out in end of 2019 hinges on or is top line data on safety is not worth listening to as they can not tell the difference between a phase I and phase II trials end point weighting. If all goes well with efficacy we will enter into a larger phase II tiral that will differentiate between standard care with Termozolid and GDC-0084. Considering 66% patients to not respond to standard care the OV is just 5.8 months the data coming out this year is crucial to determine the next step in registration, but the go ahead has little to do with safety and everything to do with efficacy confirmation.
This is cleaver and unique design as it mitigates risk and increases likely hood of success but more to the point provides enough data on PK and efficacy to justify a FDA fast track registration trial.
To imply that Top line data is years down the track is simply ignorance or worse just sour grapes.
Priscilla B will presenting data this year as well and St Judes is already pre advertising some data as well which is very odd and risky for them to say the least.
KZA Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held
